Cellectis announced it is quitting its CAR-T programs and pivoting toward in vivo gene editing. The company cited a shifting therapeutic and development landscape and said the strategic change involves offloading its lead programs as it refocuses resources. The move marks a notable repositioning for a firm long associated with donor-derived cell therapy approaches, aligning with broader interest in in vivo modalities that aim to reduce manufacturing complexity. For biotech stakeholders, the pivot suggests Cellectis expects the next competitive advantage to come from delivery and durable gene editing performance rather than ex vivo engineered cell products.